SCHEMBL335288

SCHEMBL335288

Nc1nc2ccc(NC(=O)C(O)C(NC(=O)c3ccc(-c4cccnc4)cc3)c3ccccc3)cc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.54
POLB P06746 2/20 0.54
LMNA P02545 2/20 0.54
ALDH1A1 P00352 4/20 0.48
TP53 P04637 4/20 0.48
GFER P55789 1/20 0.48
HPGD P15428 2/20 0.45
HSD17B10 Q99714 1/20 0.45
RECQL P46063 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.42
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 1/20 0.41
GAA P10253 1/20 0.41
NAMPT P43490 1/20 0.41
RAB9A P51151 1/20 0.41
ABL1 P00519 1/20 0.40
FABP6 P51161 1/20 0.40
ADRB2 P07550 1/20 0.40
ADRB1 P08588 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL335948 0.94 ABL1 (0.45) MAPTPOLBLMNAALDH1A1L3MBTL1
SCHEMBL15282160 0.89 ABL1 (0.42) MAPTPOLBLMNAALDH1A1TP53
SCHEMBL336367 0.88 MAPT (0.47) MAPTPOLBLMNAALDH1A1L3MBTL1
SCHEMBL335878 0.85 ABL1 (0.43) MAPTPOLBLMNASMN1; SMN2ABL1
SCHEMBL335576 0.85 ABL1 (0.43) MAPTPOLBLMNAALDH1A1L3MBTL1
SCHEMBL336586 0.85 GRIN1 (0.44) ABL1FABP6
SCHEMBL8219489 0.85 F9 (0.43) MAPTSMN1; SMN2RAB9AABL1FABP6
SCHEMBL335390 0.85 ABL1 (0.44) MAPTPOLBALDH1A1TP53L3MBTL1
SCHEMBL336448 0.84 TYMS (0.45) MAPTABL1FABP6
SCHEMBL335501 0.84 NPC1 (0.43) MAPTSMN1; SMN2NPC1RAB9AABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP claimed
US-8097758-B2 Isoserine derivatives for use as coagulation factor IXa inhibitors SANOFI-AVENTIS (FR) 2012-01-17 US claimed
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US claimed
CN-101516834-A Isoserine derivatives for use as coagulation factor ixa inhibitors SANOFI AVENTIS (FR) 2009-08-26 CN claimed
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP disclosed
CN-1359423-A Herbicide resistant plants HINZENTA CO LTD (GB) 2002-07-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS TFPI, F2, F9 MAPT 3998/4885POLB 3780/4885LMNA 2062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.